Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NSD2 | O96028 | 7/20 | 0.55 |
| ▸ | DNMT3A | Q9Y6K1 | 3/20 | 0.54 |
| ▸ | EHMT2 | Q96KQ7 | 11/20 | 0.53 |
| ▸ | KDM1A | O60341 | 4/20 | 0.53 |
| ▸ | RCOR1 | Q9UKL0 | 4/20 | 0.53 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.51 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.51 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4843684 | 0.91 | EHMT2 (0.54) | NSD2DNMT3AEHMT2KDM1ARCOR1 | |
| SCHEMBL4723403 | 0.89 | NSD2 (0.44) | NSD2DNMT3AEHMT2KDM1ARCOR1 | |
| Hydrochloric Acid SCHEMBL4140395 | 0.88 | NSD2 (0.43) | NSD2DNMT3AEHMT2KDM1ARCOR1 | |
| SCHEMBL4843272 | 0.86 | EHMT2 (0.53) | NSD2DNMT3AEHMT2KDM1ARCOR1 | |
| SCHEMBL4124644 | 0.86 | DNMT3A (0.61) | NSD2DNMT3AEHMT2KDM1ARCOR1 | |
| SCHEMBL4842648 | 0.85 | DNMT3A (0.54) | NSD2DNMT3AEHMT2KDM1ARCOR1 | |
| SCHEMBL4843291 | 0.83 | NSD2 (0.59) | NSD2DNMT3AEHMT2KDM1ARCOR1 | |
| SCHEMBL4116963 | 0.79 | DNMT3A (0.60) | NSD2DNMT3AEHMT2KDM1ARCOR1 | |
| SCHEMBL4124298 | 0.79 | NSD2 (0.44) | NSD2EHMT2KDM1ARCOR1EHMT1 | |
| SCHEMBL4130246 | 0.78 | DNMT3A (0.62) | NSD2DNMT3AEHMT2KDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| WO-2007042660-A2 | SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | AGTR1, AGTR2, AHR | NSD2 1088/4885DNMT3A 3277/4885EHMT2 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.